This virtual issue features 20 key and representative psychosis manuscripts published over the past decade in either Movement Disorders or Movement Disorders Clinical Practice. Although many important Parkinson’s disease (PD) psychosis manuscripts have been published in other journals over this time period, the chosen manuscripts span the spectrum of key research that has occurred in this area, covering prevalence, course,…
Diagnostic criteria for psychosis in Parkinson’s disease: Report of an NINDS, NIMH work group
There are no standardized diagnostic criteria for psychosis associated with Parkinson’s disease (PDPsy). As part of an NIH sponsored workshop, we reviewed the existing literature on PDPsy to provide criteria that distinguish PDPsy from other causes of psychosis. Based on these data, we propose provisional criteria for PDPsy in the style of the Diagnostic and…
Scales to assess psychosis in Parkinson’s disease: Critique and recommendations
Psychotic symptoms are a frequent occurrence in Parkinson’s disease (PD), affecting up to 50% of patients. The Movement Disorder Society established a Task Force on Rating Scales in PD, and this critique applies to published, peer-reviewed rating psychosis scales used in PD psychosis studies. Twelve psychosis scales/questionnaires were reviewed. None of the reviewed scales adequately…
REM behavior disorder, hallucinations and cognitive impairment in Parkinson’s disease: A two-year follow up
In Parkinson’s disease (PD) the presence of REM parasonnias as REM Behaviour Disorder (RBD) or vivid dreams/nightmares, is recognized as largely associated with hallucinations, even if the risk of the development of hallucinations seem not to depend on how long the REM parasomnias had been occurring. The aim of this study was to establish if…
A neuropsychological longitudinal study in Parkinson’s patients with and without hallucinations
The aim of this work was to determine the progression of cognitive impairment in Parkinson’s disease (PD) patients with or without hallucinations. Two years after the first assessment, 36 PD patients were re-evaluated on standardized neuropsychological tests, including the Frontal Assessment Battery (FAB), and on rating scales for overall cognitive functioning, functional autonomy, behavioral disorders.…
Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations
Well-formed visual hallucinations (VH) are common in patients with Parkinson’s disease (PD). The pathophysiology of VH in PD is unknown but may involve structures mediating visual processing such as the inferior temporal cortex. Serotonergic type 2A (5-HT2A) receptors have been linked to many psychiatric disorders, including psychosis. We hypothesized that enhanced 5-HT2A receptor levels may…
The changing face of Parkinson’s disease-associated psychosis: A cross-sectional study based on the new NINDS-NIMH criteria
New criteria for Parkinson’s disease-associated psychosis (PDAP) were recently proposed by a NINDS-NIMH working group. We assessed 116 consecutive unselected outpatients with PD for the existence of psychotic symptoms during the previous month, using a structured questionnaire covering the whole spectrum of PDAP symptoms. Hallucinations occurred in 42% of the patients (visual: 16%; nonvisual: 35%),…
Severity of neuropsychiatric symptoms and dopamine transporter levels in dementia with Lewy bodies: A 123I-FP-CIT SPECT study
Neuropsychiatric symptoms are frequent in dementia with Lewy bodies (DLB). Dopamine transporter (DAT) imaging with 123I-labeled ligand N-δ-(fluoropropyl)-2β-carbomethoxy-3β-(4-iodophenyl)tropene (123I-FP-CIT), which reliably measures midbrain dopaminergic dysfunction, has provided important evidence on the neurobiological substrate of some of these symptoms including apathy and depression. However, little is known on DAT levels and other distressing symptoms such as…
Visual plus nonvisual hallucinations in Parkinson’s disease: Development and evolution over 10 years
The objective of the study was to assess the development and evolution of visual and nonvisual hallucinations in patients with Parkinson’s disease over 10 years. Hallucinations increase over time, but minimal attention has been placed on nonvisual domains. We studied 60 patients with Parkinson’s disease who had never hallucinated at baseline and followed them over…
